Accretion Nutraveda IPO Details
Accretion Nutraveda IPO Summary
Accretion Nutraveda IPO opens for subscription on 28 Jan 2026 and closes on 30 Jan 2026.The IPO will be listed on BSE with the tentative listing date set for 04 Feb 2026.
Accretion Nutraveda IPO price band has been fixed at ₹122 – ₹129 per share. The face value is ₹10 per share with a lot size of 1000.
Accretion Nutraveda IPO total issue size comprises 19,20,000 shares (aggregating up to ₹24.77 Cr). This includes a fresh issue of 19,20,000 shares (aggregating up to ₹24.77 Cr). Pre-issue shareholding stands at 53,20,000, which will increase to 72,40,000 post-issue.
Accretion Nutraveda IPO carries a ₹68 (52.71%) GMP, reflecting investor sentiment.
Accretion Nutraveda IPO Lot Size :Individual Minimum is 2 lots (2,000 shares) amounting to ₹258,000. Individual Maximum is 2 lots (2,000 shares) amounting to ₹258,000. SHNI Minimum is 3 lots (3,000 shares) amounting to ₹387,000. SHNI Maximum is 7 lots (7,000 shares) amounting to ₹903,000. BHNI Minimum is 8 lots (8,000 shares) amounting to ₹1,032,000.
The Lead Managers for Accretion Nutraveda IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Sobhagya Capital Options Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Sunflower Broking. You can analyze their track record by checking the Market Maker Performance Summary report.
For detailed information, Refer to the Accretion Nutraveda Limited RHP.
Accretion Nutraveda IPO Details
Accretion Nutraveda IPO Subscription
Accretion Nutraveda IPO Application Wise Breakup
Accretion Nutraveda IPO Dates
- 28 Jan 2026Opening dateOpen
- 30 Jan 2026Closing dateClose
- 02 Feb 2026Allotment Date Allotment
- 03 Feb 2026Initiation of RefundsRefund
- 03 Feb 2026Credit of SharesCredit
- 04 Feb 2026Listing dateListing
Accretion Nutraveda IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Minimum | 2 | 2000 | ₹258,000 |
| Individual Maximum | 2 | 2000 | ₹258,000 |
| SHNI Minimum | 3 | 3000 | ₹387,000 |
| SHNI Maximum | 7 | 7000 | ₹903,000 |
| BHNI Minimum | 8 | 8000 | ₹1,032,000 |
Accretion Nutraveda IPO Reservation
Promoter Holding
Documents
Accretion Nutraveda IPO Valuations
Accretion Nutraveda Financial Information
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 16.35 | 10.86 | 4.64 | 4.06 |
| Total Income | 14.07 | 16.06 | 5.20 | 3.07 |
| Profit After Tax | 2.33 | 2.61 | 0.82 | 0.28 |
| EBITDA | 3.29 | 3.65 | 1.21 | 0.59 |
| NET Worth | 8.26 | 5.35 | 1.08 | 0.26 |
| Reserves and Surplus | 2.95 | 4.86 | 0.72 | -0.10 |
| Total Borrowing | 4.43 | 3.86 | 2.17 | 1.97 |
| Amount in ₹ Crore | ||||
About Accretion Nutraveda IPO
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and nutraceutical products across a wide range of dosage forms, including tablets, capsules, oral liquids, powders, oils, and external applications such as balms, creams, and gels.
The Company operates as a Contract Development and Manufacturing Organization (CDMO), catering to both domestic and international markets, including Sri Lanka, Singapore, and the United States of America. Its product formulations integrate classical Ayurvedic principles with modern nutraceutical science, addressing therapeutic and wellness segments such as liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness.
Accretion Nutraveda’s business operations are organised into the following verticals:
Domestic Sales and Merchant Exports (Loan License Basis), which contributed 96.62% of total revenue in FY 2024–25
Direct Exports, contributing 38%, demonstrating consistent growth in overseas markets
The Company operates a manufacturing facility located in Gujarat, covering approximately 10,763 square feet. The facility is equipped with modern infrastructure, including 13 air handling units (AHUs), segregated processing areas, and comprehensive quality control systems. The manufacturing unit holds multiple certifications, including GMP, WHO-GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, and Halal certification, and operates under a valid FSSAI license, reflecting its compliance with quality, safety, and regulatory standards.
Strength Of Accretion Nutraveda IPO
- Experienced Promoters and Management Team.
- Diverse Product Portfolio.
- Commitment to Quality Standards.
- Relationships with Clients and Suppliers.
- Business Processes and Management Framework.
Risk Of Accretion Nutraveda IPO
- The company's manufacturing operations are subject to risks, including equipment failures, accidents, and natural disasters, which could disrupt production.
- There are certain discrepancies and non-compliances noticed in some of its corporate records relating to forms filed with the Registrar of Companies, taxation authorities and other public authorities. Any penalty or action taken by any regulatory authorities in future for non- compliance with provisions of all applicable law could impact on the financial position of the Company to that extent.
- The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect its revenues and profitability.
- The company has historically derived, and may continue to derives, a significant portion of its supply from top 10 Suppliers.
- The company's Registered Office and Factory is located on premises which are not owned by the company and has been obtained on leased. Disruption of its rights as licensee/ lessee or termination of the agreements with the company's licensors/ lessors may adversely impact its operations and, consequently,the company's business, financial condition and results of operations.
- The Company is yet to place orders for the equipment, plant and machinery for the Proposed Expansion. Any delay in placing orders or procurement of such equipment, plant and machinery may delay the schedule of implementation and possibly increase the cost of commencing operations.
- The company may faces several risks associated with the construction of the building of the Proposed Expansion, which could hamper its growth, prospects, cash flows and business and financial condition.
- The Company has reported certain negative cash flows from its investing activity and financing activity, details of which are given below. Sustained negative cash flows could impact its growth and business.
- The company has not made any alternate arrangements for meeting its capital requirements for the Objects of the Issue
- The company's expansion into new product categories and business verticals and a substantial increase in the number of products offered may expose the company to new challenges and more risks.
Objectives Accretion Nutraveda IPO
1. Purchase of Machineries for Automation in existing Manufacturing unit
2. Purchase of Machineries for New Manufacturing Setup
3. Funding working capital requirements of our company
4. General corporate purposes
Company Contact Details
Accretion Nutraveda Ltd.
27 Xcelon Industrial Park-1
Vasna-Chacharwadi, TaSanand,
Ahmedabad, Gujarat, 382213
Phone: +91- 9904366177
Email: compliance@accretionnutraveda.com
Website: http://www.accretionnutraveda.com/
Registrar Contact Details
Accretion Nutraveda FAQs
The Accretion Nutraveda IPO is a SME public issue comprising 1920000 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹24.77 Cr. The issue price has been fixed at ₹129 per equity share, and the minimum application size is 1000 shares.
The IPO opens for subscription on 28 Jan 2026, and closes on 30 Jan 2026.
Kfin Technologies Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the BSE
As of now, the current GMP stands at ₹68 (52.71%).
Quick Links
Comments
